News

Data also showed that there was a statistically significant survival benefit of 52% relative risk reduction of death or graft loss at 5 years post-transplant (hazard ratio=0.477, p=0.0045).

The trial has been named the "CLEAN-CF" trial which refers to "Clearing Lungs with ENaC inhibition in Cystic Fibrosis". The CLEAN-CF study will include CF patients regardless of

Stakeholders throughout the drug development enterprise have caught the patient centricity bug and it is highly contagious. Sponsors, CROs, investigative sites, technology solution and service vendors, and ethical

Virirec, Apricus’ novel topical on-demand treatment for erectile dysfunction ("ED") is also marketed in other European countries as Vitaros and in Belgium as Vytaros. This is the fifth

The start of field-based commercialization efforts for Xalkori is part of the company’s aim to bring treatment options for challenging cancers to patients. In the US, Xalkori is

EpiTherapeutics has developed a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. Gilead Research and Development executive vice-president and

Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which AbbVie is currently developing in partnership with Genentech and Roche. It is designed to selectively inhibit the

Located in Kendall Square, the new Lilly Cambridge Innovation Center will allow leading life science experts and organizations to explore how emerging technologies and connectivity can advance drug

The program includes two replicate studies evaluating 48 week viral suppression with a two drug regimen combining dolutegravir and rilpivirine in HIV patients who have already achieved viral